Echocardiographic changes in dogs with stage B2 myxomatous mitral valve disease treated with pimobendan monotherapy

Andrew Crosland , Pablo Manuel Cortes-Sanchez , Siddharth Sudunagunta , Jonathan Bouvard, Elizabeth Bode, Geoff Culshaw, Joanna Dukes-McEwan

Research output: Contribution to journalArticlepeer-review

Abstract

The present study aimed to evaluate the effects of chronic pimobendan monotherapy on cardiac size in dogs with stage B2 myxomatous mitral valve disease (MMVD). Data from 31 dogs diagnosed with MMVD and cardiomegaly (LA/Ao ≥1.6 and LVIDdn ≥1.7) were included. The intervention group were dogs treated with pimobendan (n=24). Dogs not receiving any cardiac medication were controls (n=7). Echocardiographic changes in left atrial and left ventricular dimensions were compared over time. There was significant group x time interaction for LVIDdN (P=0.011) between diagnosis and initial follow up (median 3-6 months). There was a significant reduction in LVIDdN over time in the pimobendan group (P=0.038) but not the control group (P=0.216). There was no significant group x time interaction for LA/Ao and there was no effect of group (P=0.561), but LA/Ao in both groups decreased over time (P=0.01). Restraint is advised when prescribing pimobendan based on detection of a heart murmur where echocardiographic staging is an option. Some stage B2 dogs that received pimobendan no longer met the echocardiographic classification criteria for stage B2 MMVD and could have been misclassified as stage B1 and had their medication inappropriately withdrawn. We suggest these dogs are referred to as reverse remodelled stage B2.
Original languageEnglish
Article number594
Pages (from-to)1-10
Number of pages10
JournalVeterinary Sciences
Volume11
Issue number12
Early online date25 Nov 2024
DOIs
Publication statusE-pub ahead of print - 25 Nov 2024

Keywords / Materials (for Non-textual outputs)

  • Canine
  • degenerative mitral valve disease
  • pimobendan
  • reverse remodelling

Fingerprint

Dive into the research topics of 'Echocardiographic changes in dogs with stage B2 myxomatous mitral valve disease treated with pimobendan monotherapy'. Together they form a unique fingerprint.

Cite this